- Home
- SBGI vs URGN Comparison
SBGI vs URGN Comparison
Compare SBGI & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- URGN
- Stock Information
- Founded
- SBGI 1986
- URGN 2004
- Country
- SBGI United States
- URGN United States
- Employees
- SBGI N/A
- URGN N/A
- Industry
- SBGI Broadcasting
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- URGN Health Care
- Exchange
- SBGI Nasdaq
- URGN Nasdaq
- Market Cap
- SBGI 970.9M
- URGN 904.0M
- IPO Year
- SBGI 1995
- URGN 2017
- Fundamental
- Price
- SBGI $13.95
- URGN $18.79
- Analyst Decision
- SBGI Buy
- URGN Strong Buy
- Analyst Count
- SBGI 6
- URGN 8
- Target Price
- SBGI $20.08
- URGN $28.50
- AVG Volume (30 Days)
- SBGI 448.8K
- URGN 1.1M
- Earning Date
- SBGI 11-05-2025
- URGN 11-05-2025
- Dividend Yield
- SBGI 7.17%
- URGN N/A
- EPS Growth
- SBGI N/A
- URGN N/A
- EPS
- SBGI 0.74
- URGN N/A
- Revenue
- SBGI $3,481,000,000.00
- URGN $94,238,000.00
- Revenue This Year
- SBGI N/A
- URGN $39.63
- Revenue Next Year
- SBGI $9.52
- URGN $111.49
- P/E Ratio
- SBGI $18.82
- URGN N/A
- Revenue Growth
- SBGI 8.11
- URGN 10.85
- 52 Week Low
- SBGI $11.89
- URGN $3.42
- 52 Week High
- SBGI $18.46
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- SBGI 48.83
- URGN 48.50
- Support Level
- SBGI $13.19
- URGN $18.45
- Resistance Level
- SBGI $14.37
- URGN $21.71
- Average True Range (ATR)
- SBGI 0.39
- URGN 1.18
- MACD
- SBGI -0.03
- URGN -0.18
- Stochastic Oscillator
- SBGI 50.67
- URGN 17.51
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay-TV distributors.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.